Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03866213 · ClinicalTrials.gov registry record

Validation of a Jaundice Diagnostic and Monitoring Device for Low-Resource Settings

A clinical trial of Hyperbilirubinemia, Neonatal and Jaundice, Neonatal, sponsored by William Marsh Rice University.

Recruiting
Registry status
1,000
Enrollment target
3
Study locations

NCT03866213 is a study of Hyperbilirubinemia, Neonatal and Jaundice, Neonatal that is actively recruiting participants, run by William Marsh Rice University. The registered enrollment target is 1,000 participants. The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03866213, a study of Hyperbilirubinemia, Neonatal and Jaundice, Neonatal, is actively recruiting participants, sponsored by William Marsh Rice University.

RECRUITING
Registry status
1,000 participants
Enrollment target
3
Study locations

Study Summary

A team of researchers at Rice University in partnership with clinicians at Queen Elizabeth Central Hospital created BiliSpec, a low-cost battery-powered reader designed to immediately quantify serum bilirubin levels from a small drop of whole blood applied to a lateral flow strip. The simple and affordable BiliSpec system offers a faster and more cost-effective means to detect neonatal jaundice in under-resourced clinics and determine when phototherapy is needed. The goal of this study is to validate the accuracy of the BiliSpec device in measuring bilirubin levels in neonates relative to the laboratory spectrophotometric bilirubinometer and transcutaneous bilirubinometer measurements.

Interventions

  • DIAGNOSTIC_TEST BiliSpec

Study Locations (3)

Other

  • Queen Elizabeth Central Hospital - Blantyre
  • Kamuzu Central Hospital - Lilongwe

Texas

  • Rice University - Houston

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2019-08-01
Est. Completion 2024-08-31

Sponsor

William Marsh Rice University

8 total trials

What the Registry Record Tells You About NCT03866213

The ClinicalTrials.gov registry entry for NCT03866213 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is William Marsh Rice University, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hyperbilirubinemia, Neonatal appearing as the primary indexed condition, and to 1 intervention - of which BiliSpec is the first listed.

NCT03866213 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Other, Texas.

Frequently Asked Questions

What is clinical trial NCT03866213 about?

NCT03866213 is a clinical study titled "Validation of a Jaundice Diagnostic and Monitoring Device for Low-Resource Settings". A team of researchers at Rice University in partnership with clinicians at Queen Elizabeth Central Hospital created BiliSpec, a low-cost battery-powered reader designed to immediately quantify serum bilirubin levels from a small drop of whole blood applied to a lateral flow strip. The simple and aff...

What is the current status of trial NCT03866213?

This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2019-08-01. Estimated completion is 2024-08-31.

What conditions does trial NCT03866213 study?

This clinical trial studies the following conditions: Hyperbilirubinemia, Neonatal, Jaundice, Neonatal.

What interventions are being tested in trial NCT03866213?

The interventions under investigation include: BiliSpec (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03866213?

This trial is sponsored by William Marsh Rice University, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03866213 being conducted?

This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.